Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Resource implications of bortezomib therapy in a large UK cohort: An evaluation study.

Djebbari F, Tatarczuch M, Panitsas F, Vallance G, Sultanova M, Kothari J, Ramasamy K, Peniket A.

J Oncol Pharm Pract. 2019 Aug 7:1078155219866500. doi: 10.1177/1078155219866500. [Epub ahead of print]

PMID:
31390961
2.

Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation.

Balassa K, Salisbury R, Watson E, Lubowiecki M, Tseu B, Maouche N, Jeffery K, Misbah SA, Benamore R, Rowley L, Barton D, Pawson R, Danby R, Rocha V, Peniket A.

J Infect. 2019 Jun;78(6):461-467. doi: 10.1016/j.jinf.2019.04.004. Epub 2019 Apr 6.

PMID:
30965067
3.

Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.

Brierley CK, Jones FM, Hanlon K, Peniket AJ, Hatton C, Collins GP, Schuh A, Medd P, Clark A, Ward J, Chaganti S, Malladi R, Parker A, Craddock C, Danby R, Rocha V.

Br J Haematol. 2019 Feb;184(4):547-557. doi: 10.1111/bjh.15685. Epub 2018 Nov 22.

PMID:
30467838
4.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P.

Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16.

PMID:
30013198
5.

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C, Jeffries S, Walter C, Piechocki K, Timbs A, Danby R, Raghavan M, Peniket A, Griffiths M, Bacon A, Ward J, Wheatley K, Vyas P, Craddock C.

Blood Adv. 2016 Dec 14;1(3):193-204. doi: 10.1182/bloodadvances.2016000760. eCollection 2016 Dec 27.

6.

Provision of cellular blood components to CMV-seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres.

Morton S, Peniket A, Malladi R, Murphy MF.

Transfus Med. 2017 Dec;27(6):444-450. doi: 10.1111/tme.12461. Epub 2017 Sep 15.

PMID:
28913908
7.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.

Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N.

Bone Marrow Transplant. 2017 Nov;52(11):1519-1525. doi: 10.1038/bmt.2017.171. Epub 2017 Sep 11.

8.

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.

Miller PDE, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A, Snowden JA.

Bone Marrow Transplant. 2017 Jul;52(7):1082. doi: 10.1038/bmt.2017.87.

PMID:
28677683
9.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N.

Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86.

PMID:
28677682
10.

Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.

Hamblin A, Greenfield DM, Gilleece M, Salooja N, Kenyon M, Morris E, Glover N, Miller P, Braund H, Peniket A, Shaw BE, Snowden JA.

Bone Marrow Transplant. 2017 Jun;52(6):889-894. doi: 10.1038/bmt.2017.67. Epub 2017 Apr 24.

11.

Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience.

O'Hare P, Lucchini G, Cummins M, Veys P, Potter M, Lawson S, Vora A, Wynn R, Peniket A, Kirkland K, Pearce R, Perry J, Amrolia PJ.

Bone Marrow Transplant. 2017 Jun;52(6):825-831. doi: 10.1038/bmt.2017.3. Epub 2017 Feb 20.

PMID:
28218757
12.

Developing a dedicated dermatology service for allogeneic bone marrow transplant recipients.

Matin RN, Danby R, Gibbons E, Venning V, Rowley L, Barton D, Pawson R, Littlewood T, Reed JR, Peniket A.

Br J Dermatol. 2017 Dec;177(6):1758-1759. doi: 10.1111/bjd.15343. Epub 2017 Sep 19. No abstract available.

PMID:
28127749
13.

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.

Miller PDE, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A, Snowden JA.

Bone Marrow Transplant. 2017 May;52(5):775-777. doi: 10.1038/bmt.2016.362. Epub 2017 Jan 23. No abstract available. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1082.

14.

Measuring the resting naive sub-population of T-regulatory cells improves prediction of suppressive function of clinical grade T-regulatory products.

Lamikanra AA, Zhang W, Tsang HP, Morgan P, Smith D, Curnow E, Smythe J, Peniket A, Danby R, Roberts DJ.

Cytotherapy. 2017 Mar;19(3):440-443. doi: 10.1016/j.jcyt.2016.12.004. Epub 2017 Jan 18. No abstract available.

PMID:
28109752
15.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N.

Bone Marrow Transplant. 2017 Feb;52(2):209-215. doi: 10.1038/bmt.2016.266. Epub 2016 Nov 7. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.

PMID:
27819688
16.

Variations in practice in UK transplant centers: results of a related donor care survey.

Anthias C, Peniket A, Kirkland K, Madrigal JA, Shaw BE.

Bone Marrow Transplant. 2016 Dec;51(12):1612-1614. doi: 10.1038/bmt.2016.220. Epub 2016 Sep 5. No abstract available.

PMID:
27595287
17.

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, Lau IJ, Doondeea J, Usukhbayar B, Kennedy A, Metzner M, Goardon N, Ivey A, Allen C, Gale R, Davies B, Sternberg A, Killick S, Hunter H, Cahalin P, Price A, Carr A, Griffiths M, Virgo P, Mackinnon S, Grimwade D, Freeman S, Russell N, Craddock C, Mead A, Peniket A, Porcher C, Vyas P.

J Exp Med. 2016 Jul 25;213(8):1513-35. doi: 10.1084/jem.20151775. Epub 2016 Jul 4.

18.

Transfusion of CMV-unselected blood components may lead to inappropriate donor selection for patients subsequently undergoing allogeneic stem cell transplant.

Morton S, Danby R, Rocha V, Peniket A, Murphy MF.

Transfus Med. 2015 Dec;25(6):411-3. doi: 10.1111/tme.12264.

PMID:
26914496
19.

High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT.

Danby RD, Zhang W, Medd P, Littlewood TJ, Peniket A, Rocha V, Roberts DJ.

Bone Marrow Transplant. 2016 Jan;51(1):110-8. doi: 10.1038/bmt.2015.215. Epub 2015 Sep 21.

20.

An innovative method to generate a Good Manufacturing Practice-ready regulatory T-cell product from non-mobilized leukapheresis donors.

Zhang W, Smythe J, Frith E, Belfield H, Clarke S, Watt SM, Danby R, Benjamin S, Peniket A, Roberts DJ.

Cytotherapy. 2015 Sep;17(9):1268-79. doi: 10.1016/j.jcyt.2015.05.015.

PMID:
26276008
21.

Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.

Hall S, Danby R, Osman H, Peniket A, Rocha V, Craddock C, Murphy M, Chaganti S.

Transfus Med. 2015 Dec;25(6):418-23. doi: 10.1111/tme.12219. Epub 2015 Jun 26.

PMID:
26114211
22.

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Brierley CK, Littlewood TJ, Peniket AJ, Gregg R, Ward J, Clark A, Parker A, Malladi R, Medd P.

Bone Marrow Transplant. 2015 Jul;50(7):931-8. doi: 10.1038/bmt.2015.51. Epub 2015 Apr 13.

PMID:
25867645
23.

Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, Deconinck E, Nagler A, Mohty M.

Cancer. 2015 Apr 1;121(7):1048-55. doi: 10.1002/cncr.29163. Epub 2014 Nov 25.

24.

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.

Lau IJ, Smith D, Aitchison R, Blesing N, Roberts P, Peniket A, Yong K, Rabin N, Ramasamy K.

Ann Hematol. 2015 Apr;94(4):643-9. doi: 10.1007/s00277-014-2238-2. Epub 2014 Oct 28.

PMID:
25345871
25.

Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.

Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, Craddock C.

Bone Marrow Transplant. 2015 Jan;50(1):82-6. doi: 10.1038/bmt.2014.215. Epub 2014 Oct 6.

PMID:
25285801
26.

Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD.

Dignan FL, Aguilar S, Scarisbrick JJ, Shaw BE, Potter MN, Cavenagh J, Apperley JF, Fielding AK, Pagliuca A, Raj K, Marks DI, Peniket A, Crawley C, Koh MB, Child FJ.

Bone Marrow Transplant. 2014 May;49(5):704-8. doi: 10.1038/bmt.2014.21. Epub 2014 Feb 24.

PMID:
24566709
27.

Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.

Eyre TA, King AJ, Peniket A, Rocha V, Collins GP, Pawson R.

Transfusion. 2014 May;54(5):1231-4. doi: 10.1111/trf.12429. Epub 2013 Sep 30.

PMID:
24117899
28.

Selective depletion of FOXP3(high) cells by Fas-Fas-L-induced apoptosis occurs in CD4(+)CD25(+)-enriched populations during repeated expansion.

Zhang W, Nair S, Danby R, Peniket A, Roberts DJ.

Cytotherapy. 2013 Oct;15(10):1286-96. doi: 10.1016/j.jcyt.2013.05.021.

PMID:
23993302
29.

Quiz page September 2013: a crystal clear diagnosis.

MacEwen C, Deshraj A, Haynes R, Roberts I, Peniket A, Winearls C.

Am J Kidney Dis. 2013 Sep;62(3):xxvi-xxix. doi: 10.1053/j.ajkd.2013.05.012. No abstract available. Erratum in: Am J Kidney Dis. 2013 Dec;62(6):1230. Desraj, Anshul [corrected to Deshraj, Anshul].

PMID:
23972065
30.

Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.

Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, Shaw BE, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G; British Society of Blood and Marrow Transplantation.

Bone Marrow Transplant. 2013 Jul;48(7):982-7. doi: 10.1038/bmt.2012.261. Epub 2013 Jan 14. Erratum in: Bone Marrow Transplant. 2013 Oct;48(10):1368.

PMID:
23318533
31.

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.

Eyre T, Schwab CJ, Kinstrie R, McGuire AK, Strefford J, Peniket A, Mead A, Littlewood T, Holyoake TL, Copland M, Moorman AV, Harrison CJ, Vyas P.

Blood. 2012 Nov 22;120(22):4441-3. doi: 10.1182/blood-2012-09-456517. No abstract available.

PMID:
23175662
32.

More than skin deep? Emerging therapies for chronic cutaneous GVHD.

Rodgers CJ, Burge S, Scarisbrick J, Peniket A.

Bone Marrow Transplant. 2013 Mar;48(3):323-37. doi: 10.1038/bmt.2012.96. Epub 2012 Aug 6. Review.

PMID:
22863725
33.

Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD.

Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks DI, Amrolia P, Peniket A, Medd P, Potter MN, Shaw BE, Scarisbrick JJ.

Bone Marrow Transplant. 2012 Jun;47(6):824-30. doi: 10.1038/bmt.2011.186. Epub 2011 Sep 19.

PMID:
21927038
34.

Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.

Medd P, Monk I, Danby R, Malladi R, Clifford R, Ellis A, Roberts D, Hatton C, Vyas P, Littlewood T, Peniket A.

Int J Hematol. 2011 Sep;94(3):266-278. doi: 10.1007/s12185-011-0920-x. Epub 2011 Sep 7.

PMID:
21898174
35.

Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: diagnosis and follow-up by cardiac magnetic resonance imaging.

Cahill TJ, Chowdhury O, Myerson SG, Ormerod O, Herring N, Grimwade D, Littlewood T, Peniket A.

Circulation. 2011 Mar 15;123(10):e370-2. doi: 10.1161/CIRCULATIONAHA.110.986208. No abstract available.

PMID:
21403118
36.

Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.

Jovanovic JV, Rennie K, Culligan D, Peniket A, Lennard A, Harrison J, Vyas P, Grimwade D.

Front Oncol. 2011 Oct 25;1:35. doi: 10.3389/fonc.2011.00035. eCollection 2011.

37.

Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.

Medd P, Littlewood S, Danby R, Malladi R, Clifford R, Wareham D, Jeffery K, Ferry B, Roberts D, Peniket A, Littlewood T.

Bone Marrow Transplant. 2011 Jul;46(7):993-9. doi: 10.1038/bmt.2010.244. Epub 2010 Oct 18.

PMID:
20956951
38.

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.

Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N.

Haematologica. 2010 Jun;95(6):989-95. doi: 10.3324/haematol.2009.013920. Epub 2009 Nov 30.

39.

Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.

Mays AN, Osheroff N, Xiao Y, Wiemels JL, Felix CA, Byl JA, Saravanamuttu K, Peniket A, Corser R, Chang C, Hoyle C, Parker AN, Hasan SK, Lo-Coco F, Solomon E, Grimwade D.

Blood. 2010 Jan 14;115(2):326-30. doi: 10.1182/blood-2009-07-235051. Epub 2009 Nov 2.

40.

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.

Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J, Cavenagh JD, Craddock C, Orchard KH, Olavarria E, McQuaker G, Collin M, Marks DI; British Society of Blood and Marrow Transplantation.

Bone Marrow Transplant. 2009 May;43(9):709-15. doi: 10.1038/bmt.2008.375. Epub 2008 Nov 24.

PMID:
19029965
41.

Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.

Hunter A, Mahendra P, Wilson K, Fields P, Cook G, Peniket A, Crawley C, Hickling R, Marcus R.

Bone Marrow Transplant. 2009 Apr;43(7):563-9. doi: 10.1038/bmt.2008.363. Epub 2008 Nov 10.

PMID:
18997832
42.

No more transplantation in CML?

Littlewood T, Malladi R, Peniket A.

Blood. 2007 Dec 15;110(13):4618; author reply 4618-9. No abstract available.

PMID:
18056847
43.

hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.

Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J.

Leukemia. 2006 Apr;20(4):671-9.

PMID:
16498395
44.

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S.

J Clin Oncol. 2005 Dec 20;23(36):9387-93. Epub 2005 Nov 28.

PMID:
16314618
45.

Del(9q) acute myeloid leukaemia: clinical and cytological characteristics and prognostic implications.

Peniket AJ.

Br J Haematol. 2005 Sep;130(6):969; author reply 969. No abstract available.

PMID:
16156871
46.

Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.

Sternberg A, Killick S, Littlewood T, Hatton C, Peniket A, Seidl T, Soneji S, Leach J, Bowen D, Chapman C, Standen G, Massey E, Robinson L, Vadher B, Kaczmarski R, Janmohammed R, Clipsham K, Carr A, Vyas P.

Blood. 2005 Nov 1;106(9):2982-91. Epub 2005 Aug 2.

PMID:
16076868
47.

Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.

Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB.

Genes Chromosomes Cancer. 2005 Nov;44(3):279-91.

PMID:
16015647
48.

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Adès L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Chomienne C, Solomon E, Fenaux P, Grimwade D.

N Engl J Med. 2005 Apr 14;352(15):1529-38.

49.

Del (9q) AML: clinical and cytological characteristics and prognostic implications.

Peniket A, Wainscoat J, Side L, Daly S, Kusec R, Buck G, Wheatley K, Walker H, Chatters S, Harrison C, Boultwood J, Goldstone A, Burnett A.

Br J Haematol. 2005 Apr;129(2):210-20.

PMID:
15813849
50.

Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.

Malladi RK, Peniket AJ, Norton AE, Campbell AJ, Collins GP, Samol J, Eagleton H, Miller E, Morgenstern G, Jones J, Keen-Mcguire A, Barnardo M, Littlewood TJ.

Eur J Haematol. 2004 Aug;73(2):85-92.

PMID:
15245506

Supplemental Content

Loading ...
Support Center